← Back to Clinical Trials
RecruitingNCT04629326

PD-L1 Targeting Molecular Imaging of Solid Tumors

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionGastrointestinal Tumors
SponsorPeking University Cancer Hospital & Institute
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment20
SexALL
Min Age18 Years
Max AgeN/A
Start Date2021-07-20
Completion2024-11
Interventions
68Ga-WL12 PET/CT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.

Eligibility Criteria

Inclusion Criteria: * 1\. Aged \>18 years old; ECOG 0 or 1; * 2\. Patients with Gastrointestinal tumors; * 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1); * 4\. life expectancy \>=12 weeks. Exclusion Criteria: * 1\. Significant hepatic or renal dysfunction; * 2\. Is pregnant or ready to pregnant; * 3\. Cannot keep their states for half an hour; * 4\. Refusal to join the clinical study; * 5\. Suffering from claustrophobia or other mental diseases; * 6\. Any other situation that researchers think it is not suitable to participate in the experiment.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology